- Home
- COSM vs PCSA Comparison
COSM vs PCSA Comparison
Compare COSM & PCSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- COSM
- PCSA
- Stock Information
- Founded
- COSM 2009
- PCSA 2011
- Country
- COSM United States
- PCSA United States
- Employees
- COSM N/A
- PCSA N/A
- Industry
- COSM Other Pharmaceuticals
- PCSA Biotechnology: Pharmaceutical Preparations
- Sector
- COSM Health Care
- PCSA Health Care
- Exchange
- COSM Nasdaq
- PCSA Nasdaq
- Market Cap
- COSM 12.3M
- PCSA 12.0M
- IPO Year
- COSM 2013
- PCSA N/A
- Fundamental
- Price
- COSM $1.06
- PCSA $0.48
- Analyst Decision
- COSM
- PCSA Strong Buy
- Analyst Count
- COSM 0
- PCSA 1
- Target Price
- COSM N/A
- PCSA $1.00
- AVG Volume (30 Days)
- COSM 1.2M
- PCSA 21.2M
- Earning Date
- COSM 11-13-2025
- PCSA 10-29-2025
- Dividend Yield
- COSM N/A
- PCSA N/A
- EPS Growth
- COSM N/A
- PCSA N/A
- EPS
- COSM N/A
- PCSA N/A
- Revenue
- COSM $55,093,442.00
- PCSA N/A
- Revenue This Year
- COSM $28.14
- PCSA N/A
- Revenue Next Year
- COSM N/A
- PCSA N/A
- P/E Ratio
- COSM N/A
- PCSA N/A
- Revenue Growth
- COSM N/A
- PCSA N/A
- 52 Week Low
- COSM $0.28
- PCSA $0.15
- 52 Week High
- COSM $1.28
- PCSA $1.50
- Technical
- Relative Strength Index (RSI)
- COSM 59.88
- PCSA 86.63
- Support Level
- COSM $0.92
- PCSA $0.19
- Resistance Level
- COSM $1.27
- PCSA $0.21
- Average True Range (ATR)
- COSM 0.11
- PCSA 0.04
- MACD
- COSM -0.01
- PCSA 0.03
- Stochastic Oscillator
- COSM 45.68
- PCSA 78.50
About COSM Cosmos Health Inc.
Cosmos Health Inc is engaged in the nutraceuticals sector through its own proprietary lines of products 'Sky Premium Life' and 'Mediterranation'. Additionally, the firm is operating in the pharmaceutical sector through the provision of a broad line of branded over-the-counter drugs and branded and generic medicines. The company's focus will be on Branded Pharmaceuticals, Over-the-Counter medicines, and Generic Pharmaceuticals. It provides its products to wholesale drug distributors, wholesalers, and retail healthcare providers. The company's segment are Wholesale, Pharma Manufacturing, Nutraceuticals & Pharmaceuticals and Other. It derives maximum revenue from Wholesale Segment.
About PCSA Processa Pharmaceuticals Inc.
Processa Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on utilizing its regulatory science approach in the development of Next Generation Chemotherapy (NGC) oncology drug products. The company's strategic prioritization is to advance its pipeline of NGC proprietary small-molecule oncology drugs. The NGC products are new chemical entities, but the company works by changing the metabolism, distribution, and/or elimination of already FDA-approved cancer drugs or their active metabolites while maintaining the mechanism of how the drug kills cancer cells. The three NGC treatments in its pipeline are PCS6422 (also referred to as NGC-Cap), PCS3117, also referred to as NGC-Gemcitabine (NGC-Gem), and PCS11T, also referred to as NGC-Irinotecan (NGC-Iri).